Analysis of the Clinical Effect of Combined Drug Susceptibility to Guide Medication for Carbapenem-Resistant Klebsiella pneumoniae Patients Based on the Kirby–Bauer Disk Diffusion Method

References

• Liu P, Li X, Luo M, et al. Risk factors for carbapenem-resistant klebsiella pneumoniae infection: a meta-analysis. Microb Drug Resist. 2018;24(2):190–198. doi:10.1089/mdr.2017.006128749714
   PubMed Web of Science ®Google Scholar
• Shu LB, Lu Q, Sun RH, et al. Prevalence and phenotypic characterization of carbapenem-resistant Klebsiella pneumoniae strains recovered from sputum and fecal samples of ICU patients in Zhejiang Province, China. Infect Drug Resist. 2018;12:11–18. doi:10.2147/IDR.S17582330588043
   PubMed Web of Science ®Google Scholar
• Agyeman AA, Bergen PJ, Rao GG, et al. A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections. Int J Antimicrob Agents. 2020;55(1):105833. doi:10.1016/j.ijantimicag.2019.10.01431730892
   PubMed Web of Science ®Google Scholar
• van Duin D, Kaye KS, Neuner EA, et al. Carbapenem-resistant enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013;75(2):115–120. doi:10.1016/j.diagmicrobio.2012.11.00923290507
   PubMed Web of Science ®Google Scholar
• Zhang J, Yu L, Fu Y, et al. Tigecycline in combination with other antibiotics against clinical isolates of carbapenem-resistant Klebsiella pneumoniae in vitro. Ann Palliat Med. 2019;8(5):622–631. doi:10.21037/apm.2019.09.1131735038
   PubMed Web of Science ®Google Scholar
• van Duin D, Cober ED, Richter SS, et al. Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance. Clin Microbiol Infect. 2014;20(12):O1117–20. doi:10.1111/1469-0691.1271424931918
   PubMed Web of Science ®Google Scholar
• WHO. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organization, Geneva. 2017;7.
   Google Scholar
• Hu F, Guo Y, Yang Y, et al. China antimicrobial surveillance network (CHINET) study group. resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis. 2019;38(12):2275–2281. doi:10.1007/s10096-019-03673-131478103
   PubMed Web of Science ®Google Scholar
• Humphries RM, Ambler J, Mitchell SL, et al. CLSI methods development and standardization working group of the subcommittee on antimicrobial susceptibility testing. CLSI methods development and standardization working group best practices for evaluation of antimicrobial susceptibility tests. J Clin Microbiol. 2018;56(4):e01934–17. doi:10.1128/JCM.01934-1729367292
   PubMed Web of Science ®Google Scholar
• Nassar MSM, Hazzah WA, Bakr WMK. Evaluation of antibiotic susceptibility test results: how guilty a laboratory could be? J Egypt Public Health Assoc. 2019;94(1):4. doi:10.1186/s42506-018-0006-130686832
   PubMed Web of Science ®Google Scholar
• Matuschek E, Brown DF, Kahlmeter G. Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories. Clin Microbiol Infect. 2014;20(4):O255–266. doi:10.1111/1469-0691.1237324131428
   PubMed Web of Science ®Google Scholar
• Zheng X, Wang JF, Xu WL, et al. Clinical and molecular characteristics, risk factors and outcomes of Carbapenem-resistant Klebsiella pneumoniae bloodstream infections in the intensive care unit. Antimicrob Resist Infect Control. 2017;6(1):102. doi:10.1186/s13756-017-0256-229026535
   PubMed Web of Science ®Google Scholar
• Tian D, Pan F, Wang C, et al. Resistance phenotype and clinical molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae among pediatric patients in Shanghai. Infect Drug Resist. 2018;11:1935–1943. doi:10.2147/IDR.S17558430498365
   PubMed Web of Science ®Google Scholar
• Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16(1):18. doi:10.1186/s12941-017-0191-328356109
   PubMed Web of Science ®Google Scholar
• Kohler PP, Volling C, Green K, et al. Carbapenem resistance, initial antibiotic therapy, and mortality in Klebsiella pneumoniae bacteremia: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2017;38(11):1319–1328. doi:10.1017/ice.2017.19728950924
   PubMed Web of Science ®Google Scholar
• Del Mar Tomas M, Cartelle M, Pertega S, et al. Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect. 2005;11(7):540–546. doi:10.1111/j.1469-0691.2005.01184.x15966971
   PubMed Web of Science ®Google Scholar
• Robilotti E, Deresinski S. Carbapenemase-producing Klebsiella pneumoniae. F1000Prime Rep. 2014;6:80. doi:10.12703/P6-8025343037
   PubMedGoogle Scholar
• Ojdana D, Gutowska A, Sacha P, et al. Activity of ceftazidime-avibactam alone and in combination with ertapenem, fosfomycin, and tigecycline against carbapenemase-producing Klebsiella pneumoniae. Microb Drug Resist. 2019;25(9):1357–1364. doi:10.1089/mdr.2018.023431295055
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Kazmierczak KM, Young K, et al. In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum β-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016). Diagn Microbiol Infect Dis. 2020;96(4):114925. doi:10.1016/j.diagmicrobio.2019.11492531954597
   PubMed Web of Science ®Google Scholar
• Ji S, Lv F, Du X, et al. Cefepime combined with amoxicillin/clavulanic acid: a new choice for the KPC-producing K. pneumoniae infection. Int J Infect Dis. 2015;38:108–114. doi:10.1016/j.ijid.2015.07.02426255892
   PubMed Web of Science ®Google Scholar
• Watkins RR, Deresinski S. Is combination therapy for carbapenem-resistant Klebsiella pneumoniae the new standard of care? Expert Rev Anti Infect Ther. 2015;13(4):405–407. doi:10.1586/14787210.2015.101882525711690
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Pagano L, Martino B, et al. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol. 2016;91(11):1076–1081. doi:10.1002/ajh.2448927428072
   PubMed Web of Science ®Google Scholar